Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The p53 mutation "gradient effect" and its clinical implications.

Gerard P Zambetti1

  • 1Department of Biochemistry, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA. gerard.zambetti@stjude.org

Journal of Cellular Physiology
|August 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.

Cell reports·2026
Same author

Reconstructing the Origin and Demographic Expansion of the TP53 p.R337H Founder Variant in Brazil.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2025
Same author

A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.

Genome medicine·2025
Same author

Cancer associated to low-penetrance TP53 variants: insights from p.R337H.

Trends in cancer·2025
Same author

Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery.

Cancer management and research·2024
Same author

Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.

Nature communications·2023

The p53 tumor suppressor pathway is often lost in cancer. This review explores how partial or full p53 loss impacts tumor development and clinical outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor pathway is crucial for preventing cancer.
  • Inactivation of p53 is a common event in human cancers.
  • The extent of p53 inactivation can vary, influencing cancer progression.

Purpose of the Study:

  • To review recent findings on the functional consequences of p53 inactivation in cancer.
  • To highlight the concept of a p53 functional gradient.
  • To discuss the clinical implications of varying p53 activity levels.

Main Methods:

  • Review of recent human cancer studies.
  • Analysis of data from genetically engineered mouse models.
  • Synthesis of current knowledge on p53 signaling in tumorigenesis.

Related Experiment Videos

Main Results:

  • Evidence supports a gradient effect of p53 function, where residual activity influences tumor phenotype.
  • Different mechanisms of p53 targeting lead to distinct levels of functional loss.
  • The degree of p53 activity loss correlates with specific tumor characteristics.

Conclusions:

  • The level of remaining p53 activity is a critical determinant of tumor behavior.
  • Understanding the p53 functional gradient offers insights into cancer development.
  • This concept has potential implications for cancer treatment strategies.